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ABSTRACT
Gastric cancer is the fourth most common cancer and the second leading cause of cancer deaths
worldwide. Additionally, it is well-known that metastatic cancer disease is a major cause of morbidity
and mortality in cancer patients. Several investigations reported that HER-2 (ErbB-2 receptor) and
Epstein-Barr virus (EBV) are important etiological factors in human gastric cancer, where either
oncogene/oncovirus alone can derive a major event of cancer progression and metastasis via
epithelial–mesenchymal transition (EMT). Herein, we discuss, for the first time, the possibility of HER-2/
EBV-oncoproteins interaction in human gastric cancer initiation and/or progression.
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Gastric cancer is a major health problem worldwide,
causing approximately one million deaths per year and
ranking as the second leading cause of cancer-related
deaths due to metastasis. Although the role of HER-2
(ErbB-2) in this tumor has already been extensively
explored, and found to be frequently associated with
invasion, high grade, and unfavorable prognosis, its over-
all prognostic role remains uncertain and appears to be
stage-dependent.1 In this regard, the seminar paper by
Van Cutsem et al.2 on gastric cancer elegantly discussed
important parameters related to this malignancy, espe-
cially new and promising agents targeting the HER-2
receptor (as »20% of these cancers are HER-2 positive);
Additionally, the authors highlighted the potential role
of Epstein-Barr virus (EBV) in human gastric cancer
especially gastroesophageal junction adenocarcinomas
since 81% of these malignancies are positive for this virus
in men.
HER-2 (ErbB-2, c-erbB2 or Her-2/neu), is a member
of the HER-family that also includes HER-1 (Epidermal
Growth Factor Receptor-EGFR, or ErbB1), HER-3
(ErbB-3) and HER-4 (ErbB-4); HER-2 is a proto-
oncogene that encodes for a 185-kDa plasma mem-
brane-bound receptor.3,4 The ErbB family belongs to
transmembrane growth factor receptors defined by a
glycosylated extracellular domain to which peptide
growth factor ligands bind, a single transmembrane
region, and a cytoplasmic domain with tyrosine kinase
activity, which has a decisive role in the regulation of
fundamental signaling transduction pathways in both
normal and cancer cells.4,5 These receptors can be
stimulated by extracellular signals and/or independent
homodimerization or heterodimerization leading to the
activation of downstream pathways such as mitogen-
activated protein kinase (MAPK), phosphoinositide-
3-kinase (PI3K), phospholipase C and protein kinase C,
inducing signal transduction and transcription (Fig. 1).5
As such, HER-2 gene amplification and protein overex-
pression are involved in the pathogenesis and progres-
sion of several human carcinomas, thus they are often
considered as a poor prognostic factor.4,5 Since HER-2 is
overexpressed in many epithelial malignancies including
breast and gastric cancer, it has been regarded as an
important potential therapeutic target for several human
carcinomas especially breast.3 Accordingly, antibodies
and tyrosine kinase inhibitors were developed to treat
human carcinomas expressing HER-1 and HER-2 and/
or HER-2 alone.5 To date, although numerous targeted
agents have been tested in randomized trials, however,
only trastuzumab (in HER2-positive patients) and ramu-
cirumab (in an unselected population) are currently
approved in gastric cancer management.6
The EBV was discovered as the etiologic agent
responsible of Burkitt’s lymphoma, an unusual African
pediatric lymphoma, in 1964, making it the first identi-
fied human tumor-causing virus.7,8 EBV is an ubiquitous
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human herpesvirus 4 (HHV4) that establishes latent
infections in >90% of the adult population worldwide.7
This virus is composed of a linear, double-stranded
DNA, protected by a 100nm in diameter icosahedral
nucleocapsid composed by 162 capsomers, which is usu-
ally found in the episomal form inside cells.8 EBV
genome has 172,000 bp and although it can potentially
codify more than 85 proteins, only a few are well known:
there are 6 nuclear antigens (EBNA 1, 2, 3A, 3B, and 3C,
and EBNA-LP); 3 latent membrane proteins (LMPs 1,
2A, 2B) also known as latent genes; small non-
polyadenylated RNAs, EBER 1 and 2; microRNAs (miR-
BHRF1 and miR-BART); and several early lytic genes.9,10
EBV is considered an etiological factor in multiple malig-
nancies of either lymphoid or epithelial origin, including
Burkitt lymphoma, Hodgkin’s lymphoma,
gastric and nasopharyngeal carcinomas, suggesting its
primary tropism for these tissue cells.8,10 To date, most
studies have focused on EBV-encoded proteins such as
the latent nuclear antigen EBNA1 and the latent mem-
brane proteins “oncoproteins” LMP1, LMP2A and
LMP2B, which have the ability to transform cells and
cause gene alteration and consequently enhance cell pro-
liferation, survival and invasion of transformed cells.11,12
However, EBV-associated tumors generally express a
restricted repertoire of EBV-oncoproteins in a histologi-
cal specific fashion,12 suggesting that the pathogenesis
and progression of these tumors are not only regulated
by these oncoproteins but also by other important factors
such as EBV-encoded microRNAs, as demonstrated
recently by Cai et al.13 In addition, it was revealed that
EBV oncoproteins (LMP1 and EBNA1) can enhance
gastric cancer progression via the initiation of the epithe-
lial-mesenchymal transition (EMT) event by modulating
PI3/Akt/GSK-b and Shc-MAPK/Erk1/Erk2 signaling
pathways which can lead to nuclear accumulation of
b-catenin and enhancing cancer metastasis (Fig. 1).13
As we mentioned above, it is known that activated
HER-2 (hetero- and homo-dimer) proteins initiate phos-
phorylation events that lead to the activation of several
signaling pathways, all of which are implicated in breast
cancer progression.3 These pathways include STAT3,
Erk1/ErK2, and PI3/Akt which can initiate EMT and
consequently cancer progression and metastasis
(Fig. 1).4,14 Based on the fact that oncovirus infection
alone is not sufficient to induce neoplastic transforma-
tion of normal epithelial cells; the infected cells must
undergo additional genetic changes and/or co-infection
with another oncovirus to reach full transformation and
consequently tumor formation. Therefore, we have
demonstrated that HER-2 can cooperate with E6/E7
oncoproteins of HPV type 16 to induce cellular transfor-
mation of human normal oral epithelial (NOE) cells; this
was accompanied by a de-localization of b-catenin from
the undercoat membrane to the nucleus.15 Furthermore,
we reported that cyclin D1 is the downstream target of
HER-2/E6/E7 cooperation via the conversion of b-cate-
nin’s role from a cell-cell adhesion molecule to a nuclear
transcriptional regulator.16 Finally, we were able to show
that the cooperation effect of HER-2 with E6/E7
oncoproteins, in human oral epithelial cells, occurs via
b-catenin tyrosine phosphorylation through pp60
(c-Src) kinase activation.4 On the other hand, we demon-
strated that HER-2 can cooperate with E6/E7 of HPV
type 16 to enhance breast tumorigenesis in vivo using
double transgenic mice.4
Therefore, and based on Van Cutsem’s paper and
other investigations related to HER-2 and EBV in gastric
cancer; in addition to our own study on HER-2/E6/E7
cooperation in human oral cells, we are proposing that
HER-2 could cooperate with EBV oncoproteins in
human gastric cancer development and/or progression.
This initiation and enhancement of the EMT event can
be concomitant with crosstalk between HER-2 and EBV
signaling pathways eliciting a spectrum of genes
deregulation linked with gastric carcinogenesis (Fig. 1).
Meanwhile, it is important to mention that a previous
study conducted by Zang et al.17 revealed that HER-2
expression in EBV-associated gastric carcinoma cases is
less than EBV-negative gastric carcinomas, and none of
LMP2A oncoprotein-positive cases showed a high
expression of HER-2. Additionally, the same group
pointed-out that overexpressing LMP2A of EBV in EBV-
negative gastric cells could decrease the expression of
HER-2. We believe that the data of this study need
Figure 1. Schematic outline showing potential cooperation
between HER-2 and EBV oncoproteins in human gastric cancer
initiation and/or progression. We note that HER-2 and EBV onco-
proteins share various downstream-signaling pathways, including
SRC/b-catenin, PI3k/Akt/mTOR and RAS/MEK/ERK; thus, HER-2/
EBV activation pathways could initiate cancer development and/
or enhance malignancy progression via the deregulation of cell
differentiation (EMT), proliferation, apoptosis and angiogenesis.
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confirmation in addition to mechanistic investigation
regarding the functional domain of LMP2A on the
deregulation of HER2. However, and based on the large
number of investigations regarding the overexpression of
HER-2 and the presence of EBV in human gastric cancer
especially gastroesophageal junction adenocarcinomas,
we consider that HER-2 and EBV crosstalk can play an
important role in human gastric carcinogenesis.
In conclusion, it is evident that HER-2 and EBV can
be co-present in human gastric carcinomas, as illustrated
by Van Cutsem et al.2 and others,18 which could pro-
voke/enhance the initiation and progression of these
cancers. Thus, the role of EBV and particularly the coop-
eration effect between its oncoporteins and HER-2 in
gastric carcinogenesis needs thorough investigation.
Therefore, we believe that more molecular and cellular
studies, in addition to developing in vivo models, are
necessary to elucidate the cooperation outcome of HER-
2/EBV oncoproteins especially LMP1 and EBNA1 in this
prevalent cancer, which may lead to the identification of
new gene therapy targets. Finally, we think that future
EBV vaccines could have a considerable impact on EBV-
associated cancers and their metastatic forms,19 which
are responsible for the majority of cancer-related deaths.
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